Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
Servicio de Microbiología y Parasitología Clínica, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Parasitol Res. 2020 Jun;119(6):1915-1923. doi: 10.1007/s00436-020-06688-2. Epub 2020 May 14.
Trichomoniasis is the most prevalent curable sexually transmitted infection (STI) worldwide and a risk factor for the acquisition of other STIs and adverse pregnancy outcomes. The objectives of this study were to determine the prevalence of T. vaginalis and related coinfections in women attending a third-level hospital of Madrid (Spain). A retrospective study of 24,173 vaginal exudates from women with suspected vaginitis was conducted between 2013 and 2017. Likewise, among T. vaginalis positive samples, co-occurrence with gonorrhea, chlamydia, syphilis, VIH, Mycoplasma hominis, and Ureaplasma urealyticum was checked. Moreover, seven T. vaginalis isolates from 2017 were randomly collected for endobionts, drug resistance, and microsatellite (MS) instability determinations. The prevalence of T. vaginalis was 0.8% between 2013 and 2017. Less than 20% of patients with trichomoniasis were submitted to a complete screening for other genital pathogens. From that, two patients were coinfected with chlamydia and three with syphilis. Surprisingly, 6.4% of positive samples were diagnosed among pregnant women, showing an alarming increase from 3.2% (2014) to 10% (2017). Among the isolates randomly analyzed, five carried T. vaginalis virus, five harbored mycoplasmas, and one was metronidazole-resistant. The molecular genotyping showed a high variability in the three MS evaluated. To our knowledge, this is the first study in Spain that evaluates the prevalence of trichomoniasis in general and pregnant population and includes biomolecular determinations. These results warn about the increasing prevalence and highlight the importance of including T. vaginalis detection in routine gynecological revisions with special emphasis on childbearing age women and patients with previous STIs.
滴虫病是全球最常见的可治愈性性传播感染(STI),也是获得其他 STI 和不良妊娠结局的风险因素。本研究的目的是确定马德里三级医院就诊的女性阴道滴虫病和相关合并感染的流行率。对 2013 年至 2017 年间疑似阴道炎的 24173 例阴道分泌物进行了回顾性研究。同样,在阴道毛滴虫阳性样本中,检查了淋病、衣原体、梅毒、艾滋病毒、人型支原体和脲原体的合并感染情况。此外,2017 年从 7 例阴道毛滴虫分离株中随机采集内共生体、耐药性和微卫星(MS)不稳定性进行检测。2013 年至 2017 年期间,阴道毛滴虫的患病率为 0.8%。不到 20%的滴虫病患者接受了其他生殖病原体的全面筛查。从这些患者中,有 2 例合并感染衣原体,3 例合并感染梅毒。令人惊讶的是,6.4%的阳性样本是在孕妇中诊断出来的,从 2014 年的 3.2%到 2017 年的 10%呈明显上升趋势。在随机分析的分离株中,5 株携带阴道毛滴虫病毒,5 株携带支原体,1 株对甲硝唑耐药。分子基因分型显示,在评估的 3 个 MS 中有很高的变异性。据我们所知,这是西班牙第一项评估普通人群和孕妇滴虫病流行率的研究,包括生物分子测定。这些结果警示了患病率不断上升的情况,并强调了在常规妇科检查中检测阴道毛滴虫的重要性,特别是要重点关注育龄妇女和有既往性传播感染的患者。